厌食
兴奋剂
痛苦
药理学
敌手
对抗
医学
机制(生物学)
受体
生物信息学
肥胖
内科学
药品
药物发现
G蛋白偶联受体
受体拮抗剂
B2受体
作用机理
右芬氟拉明
内分泌学
药物开发
临床疗效
作者
Iona Davies,Jens J. Holst,Mette M. Rosenkilde,Tricia Tan
标识
DOI:10.1146/annurev-nutr-061824-043740
摘要
Glucagon-like peptide-1 (GLP-1)-based obesity pharmacotherapies have revolutionized obesity treatment. In this review, we discuss the discovery of GLP-1 and evaluate the efficacy of marketed and investigational GLP-1 receptor (GLP-1R) agonists (GLP-1RAs), most notably semaglutide, as well as their potential central mechanism of action. We highlight the GLP-1R/glucose-dependent insulinotropic polypeptide receptor (GIPR) dual agonist tirzepatide and the GLP-1RA/GIPR antagonist maridebart cafraglutide, discussing how both methods of GIPR targeting can produce beneficial metabolic effects. The lack of evidence for the anorectic effects of GIPR agonism or antagonism alone in humans is noted, and the review concludes with an evaluation of other reasons for the greater efficacy of GIPR/GLP-1R dual targeting compounds over semaglutide.
科研通智能强力驱动
Strongly Powered by AbleSci AI